Cure My Disease

Don't miss your cure!

 Log in / Sign up

New imaging study reveals how immune drugs impact lung scarring

NCT ID NCT07572383

Recruiting now Knowledge-focused Sponsor: Peter Caravan Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 15, 2026 · Updated 2 times

Summary

This study looks at how immunosuppression treatment changes lung scarring in people with certain types of interstitial lung disease (not IPF). Using advanced PET and MRI scans, researchers will measure collagen buildup and tissue damage. The goal is to better understand the effects of treatment, not to cure or control the disease directly.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC HYPERSENSITIVITY PNEUMONITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hypersensitivity pneumonitis interstitial lung disease pulmonary fibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

INTERSTITIAL LUNG DISEASE PULMONARY FIBROSIS

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Massachusetts General Hospital

    RECRUITING

    Boston, Massachusetts, 02114, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.